Protein Summary
May inhibit NODAL and BMP signaling during neural patterning (By similarity). May be a tumor suppressor in brain cancers. This locus represents naturally occurring read-through transcription from the neighboring MSANTD3 (Myb/SANT-like DNA-binding domain containing 3) and TMEFF1 (transmembrane protein with EGF-like and two follistatin-like domains 1) genes. The read-through transcript encodes a fusion protein that shares sequence identity with the products of each individual gene. [provided by RefSeq, Aug 2013]
- ENST00000374879
- ENSP00000364013
- ENSG00000241697
- C9orf2
- TR-1
- H7365
- C9orf2
- TMEFF1
- C9orf3-TMEFF1
- C9orf30-TMEFF1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
PubMedID | 0.85 | ||
transcription factor binding site profile | 0.62 | ||
gene perturbation | 0.61 | ||
transcription factor perturbation | 0.61 | ||
small molecule perturbation | 0.59 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 14.12 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 199 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 14.12 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 199 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Term: 1
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0